Med Cause -

Credit: Unsplash/CC0 Public Domain

Anglo-Swedish pharmaceuticals giant AstraZeneca on Thursday agreed to buy French biotech specialist Amolyt Pharma for about $1 billion, expanding further into the field of rare drugs.

“AstraZeneca … has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases,” it said in a statement.
The London-listed group added that the transaction would bolster its rare diseases division Alexion.
It will pay $800 million upfront for the Lyon-based company, plus an additional payment of $250 million payable after a specified regulatory milestone is reached.
“We enthusiastically welcome the proposed acquisition of Amolyt by AstraZeneca, an organization that shares our dedication to delivering life-changing treatments to people living with rare diseases,” added Amolyt Pharma chief executive Thierry Abribat.
“This agreement offers the opportunity to meaningfully advance our pipeline therapies.”
AstraZeneca’s share price was up 0.1 percent in early morning London trading following the news.
“The deal adds weight behind Astra’s rare disease division,” said Sophie Lund-Yates, lead equity analyst at stockbroker Hargreaves Lansdown, noting that Amoly is developing a treatment for an endocrine disorder which is in the final phase of clinical trials.
“This addition to the pipeline looks to be potentially lucrative.”
The transaction is expected to close by the end of the third quarter.

© 2024 AFP

AstraZeneca buys French biotech firm Amolyt for $1 bn (2024, March 14)
retrieved 19 March 2024

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Share this article
Shareable URL
Prev Post
Next Post
Leave a Reply

Your email address will not be published. Required fields are marked *

Read next
Credit: Pixabay/CC0 Public Domain A new study reveals that many people living in extreme poverty in low- and…
Credit: Anna Shvets from Pexels US pharmaceutical and cosmetics giant Johnson & Johnson has agreed to pay…
Need Help?